Tianhe issues policies to boost modern urban industry

en.thnet.gov.cn Updated: April 2, 2024

Guangzhou's Tianhe district issued some preferential policies on March 26 to boost the high-quality development of its modern urban industry by focusing on the four fields of energy supply, urban consumption, intelligent manufacturing, and life health.

A reward that is equal to 1 percent of their industrial output value is set to be granted to energy supply companies with an industrial output value of more than 1 billion yuan ($138.33 million) in the first fiscal year after they newly registered in Guangzhou, urban consumption ones with over 100 million yuan, or intelligent manufacturing and life health enterprises with over 50 million yuan. The maximum reward amount shall be at most 20 million yuan.

Those who successfully introduce a Fortune Global 500 company, a national-level "little giant" enterprise, a single-product champion enterprise, a listed company, or a headquarters one in the modern urban industry are set to be given a maximum reward of 2 million yuan.

未标题-2.jpg

Vibrant Tianhe district. [Photo/Nanfang Plus]

Modern urban industrial enterprises above the designated size that are recognized as the national manufacturing single-product champion or a "little giant" enterprise for the first time are set to be granted 2.5 million yuan and 1 million yuan, respectively. In comparison, those titled provincial manufacturing single-product champions are set to get 500,000 yuan. If identified as a national-level enterprise technology center or a manufacturing innovation center for the first time, they are set to be rewarded 1 million yuan and 500,000 yuan for becoming provincial-level ones.

Biomedical R&D institutions in Tianhe that obtain clinical trial approval from the State Administration for Market Regulation are set to be funded in stages that are equal to 40 percent of its actual cost of clinical R&D: a maximum of 10, 20, and 30 million yuan, respectively, for the completion of phase-1, phase-2, and phase-3 clinical trials. The total amount for each enterprise shall be at most 80 million yuan per year.

Those newly obtaining a drug certificate or getting a drug registration approval are set to be granted a maximum of 8 million yuan for each certificate or approval, with a total amount of no more than 16 million yuan for each enterprise each year.

Manufacturing enterprises implementing new technology transformation projects with an investment of over 5 million yuan are rewarded equal to their actual investment amount, with a maximum of 10 million yuan.